Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer

Abstract

Objective. Chemotherapy-associated peripheral neuropathy (CAPN) is a painful side-effect of chemotherapy. This study assesses healthcare and workloss costs of CAPN patients with breast, ovarian, head/neck, or non-small cell lung cancer (NSCLC) from a third-party payor/employer perspective. Research Design and Methods. Patients with qualifying tumors, and claims for chemotherapy and services indicative of peripheral neuropathy (PN) within 9-months of chemotherapy (cases) were identified in a administrative claims database. Cases were matched 1 : 1 to controls with no PN-related claims based on demographics, diabetes history and propensity for having a diagnosis of PN during the study period (based on resource use and comorbidities in a 3-month baseline period). Average all-cause healthcare costs, resource use and workloss burden were determined. Results. Average healthcare costs were $17,344 higher for CAPN cases than their non-CAPN controls, with outpatient costs being the highest component (with cases having excess costs of $8,092). On average, each CAPN case had 12 more outpatient visits than controls, and spent more days in the hospital. Workloss burden was higher for cases but not statistically different from controls. Conclusion. This study establishes that breast, ovarian, head/neck, or NSCLC patients with CAPN have significant excess healthcare costs and resource use.

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy

“…This conservative gait pattern, which is different from that of normal walking, 44 is associated with fall risk in aging and diabetic peripheral neuropathy 40-42 and stems from decreased proprioceptive sensory feedback to the lower extremities, ankle weakness, and foot pain. 33 The significance between groups in terms of gait patterns disappeared after final adjustment for BMI and physical activity, indicating a potential interplay between these factors and CIPN symptoms on gait that is worth additional study.…”

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial

“…Adverse events [19] Disutility [24] Cost per event [13,31,32] -$2 ,500 -$2,0 00 -$1 ,500 -$1,0 00 -$5 00 $0 $50 0 $1,0 00 $1,500 $2,0 00 $2,5 00 The results from the PSA are shown in the scatter plot, which represents the joint distribution of the difference in costs and QALYs (Fig. 3A).…”

“…It was conservatively assumed that most AEs were managed by one additional outpatient office visit, except for rash, diarrhea, and neutropenia which required additional procedures (e.g., inpatient physician visits, red blood cell transfusions, or additional drugs). Costs to manage neurological AEs (not reported by Carlson et al) were the average of costs from two published studies on chemotherapy-induced neurological toxicity among cancer patients [31,32]. See Table 2 Costs Proteomic test $3260 Drug acquisition Chemotherapy Erlotinib Docetaxel among all chemotherapy [29] 62.9% Cost [27] $3178 $6591 No.…”

Novel High-Throughput Drug Screening Platform for Chemotherapy-Induced Axonal Neuropathy

“…Chemotherapy-induced peripheral neuropathy (CIPN) is the most common dose-limiting neurotoxicity from anti-cancer drug therapy [1,2]. Platinum drugs, taxanes, proteasome inhibitors, vinca alkaloids, epothilones, and immunomodulators are the standard of anti-cancer therapies for the six most cancers.…”